Compare GSK plc (GSK) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? GSK plc trades at $52.65 (market cap $101.34B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $107.49. The key difference: GSK plc pays a 3.49% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none, and GSK plc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| GSK | LQD | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | — |
52-Week High | $61.18 | $112.91 |
52-Week Low | $36.20 | $106.96 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
LQD trades at $107.335, up 0.12% on the day, with a bearish technical signal driven by moving averages. The ETF shows oversold RSI readings below 30, indicating potential for a near-term bounce. Recent dividends include $0.42 paid in May 2026, with fixed income ETFs gaining investor attention amid economic uncertainty.
Outlook remains cautious due to bearish technicals and interest rate sensitivity. Opportunities exist for income-focused investors via dividends, but risks include Fed policy shifts and inflation pressures. Bond ETF flows are strong, yet narrowing market breadth caps conviction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
